Emyria’s Dr Michael Winlo brings investors up to speed on a phase one trial for the company’s ultra-pure cannabidiol (CBD) capsules. The final patients in a 12-person cohort will be dosed with the EMD-RX5 formulation in Adelaide today. Dr Winlo believes EMD-RX5 has the potential to address multiple clinical indications as a registered medicine where low doses of CBD appear to be effective, but it’s first targeting registration as an over-the-counter treatment for psychological distress.